Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Organon: Humira A ‘Whole Different Animal’ To Other US Biosimilars

US-Based Firm Also In Discussions To Expand Biosimilar Pipeline

Executive Summary

Shortly after filing for a high-concentration biosimilar adalimumab product with partner Samsung Bioepis, Organon has provided in-depth commentary for its expectations around the impending formation of the market, forecasting a “free for all” six months post-formation.

You may also be interested in...



Teva Confident On US Adalimumab Filing Amid Alvotech Advantages

A delay in FDA approval for partner Alvotech’s proposed high-concentration biosimilar version of Humira has not concerned Teva, especially after the product was approved by the EMA at the end of last year. There “shouldn’t really be any challenges here,” management says.

Coherus Inks $300m Credit Agreement With Ranibizumab Approval Worth $50m

Presenting at the 40th Annual J.P. Morgan Health Care Conference, Coherus BioSciences provided the latest on the firm’s highly-anticipated proposed on-body injector device for pegfilgrastim, days after securing a $300m credit agreement that includes $50m related to the firm’s proposed ranibizumab biosimilar.

Samsung Bioepis Aims To Compete On Higher-Strength Humira In US

Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB151548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel